Charles Schwab Investment Management Inc. Acquires 79,650 Shares of Solventum Corporation $SOLV

Charles Schwab Investment Management Inc. increased its holdings in Solventum Corporation (NYSE:SOLV) by 6.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,253,610 shares of the company’s stock after purchasing an additional 79,650 shares during the period. Charles Schwab Investment Management Inc. owned 0.72% of Solventum worth $95,074,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SOLV. Strengthening Families & Communities LLC raised its position in shares of Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares during the last quarter. Barrett & Company Inc. grew its stake in Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares in the last quarter. IMG Wealth Management Inc. bought a new stake in Solventum in the 2nd quarter valued at $31,000. MTM Investment Management LLC purchased a new stake in Solventum in the 2nd quarter worth $40,000. Finally, Smartleaf Asset Management LLC lifted its stake in Solventum by 193.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after purchasing an additional 352 shares in the last quarter.

Analyst Upgrades and Downgrades

SOLV has been the subject of a number of research analyst reports. Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research report on Sunday, November 23rd. UBS Group reissued a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Wells Fargo & Company lifted their price objective on Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Monday, September 15th. Piper Sandler upped their price objective on Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Jefferies Financial Group started coverage on shares of Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $85.56.

Solventum Price Performance

NYSE:SOLV opened at $84.32 on Friday. The firm has a market capitalization of $14.63 billion, a price-to-earnings ratio of 9.71, a PEG ratio of 9.00 and a beta of 0.48. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The business has a 50 day simple moving average of $73.77 and a 200-day simple moving average of $73.64. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $86.81.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.07. The company had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.Solventum’s quarterly revenue was up .7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Solventum declared that its board has approved a share repurchase program on Thursday, November 20th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to purchase up to 7.5% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.